{"name":"Cogent Biosciences","slug":"cogent","ticker":"COGT","exchange":"NASDAQ","domain":"cogentbio.com","description":"Cogent Biosciences is a precision oncology company focused on developing targeted therapies for genetically defined cancers. The company's lead product, ezurastat, is a small molecule inhibitor of the RAS pathway. Cogent Biosciences is a relatively small player in the precision oncology market, but its product has shown promise in clinical trials.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Andy Boral","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.1B","metrics":{"revenue":7871000,"revenueGrowth":0,"grossMargin":0,"rdSpend":269780000,"netIncome":-328937000,"cash":937607000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ezurastat patent cliff ($0.00 at risk)","drug":"ezurastat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CGT9486","genericName":"CGT9486","slug":"cgt9486","indication":"Acute myeloid leukemia (AML) with FLT3 mutations","status":"phase_3"},{"name":"CGT9486 plus sunitinib","genericName":"CGT9486 plus sunitinib","slug":"cgt9486-plus-sunitinib","indication":"Acute myeloid leukemia with FLT3 mutations","status":"phase_3"}]}],"pipeline":[{"name":"CGT9486","genericName":"CGT9486","slug":"cgt9486","phase":"phase_3","mechanism":"CGT9486 is a selective tyrosine kinase inhibitor that targets FLT3, a receptor implicated in acute myeloid leukemia and other hematologic malignancies.","indications":["Acute myeloid leukemia (AML) with FLT3 mutations"],"catalyst":""},{"name":"CGT9486 plus sunitinib","genericName":"CGT9486 plus sunitinib","slug":"cgt9486-plus-sunitinib","phase":"phase_3","mechanism":"CGT9486 is a selective FLT3 inhibitor combined with sunitinib, a multi-targeted tyrosine kinase inhibitor, to block FLT3 and PDGFR signaling in acute myeloid leukemia.","indications":["Acute myeloid leukemia with FLT3 mutations"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Cogent Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Cogent Biosciences reported its financial results for the fourth quarter and full year 2022, including revenue and net loss.","drugName":"","sentiment":"neutral"},{"date":"2022-12-15","type":"deal","headline":"Cogent Biosciences Announces Collaboration with National Cancer Institute","summary":"Cogent Biosciences announced a collaboration with the National Cancer Institute to develop new cancer therapies.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"trial","headline":"Cogent Biosciences Announces Positive Interim Results from Phase 1/2 Clinical Trial of Ezurastat","summary":"Cogent Biosciences announced positive interim results from a Phase 1/2 clinical trial of its lead product, ezurastat.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"regulatory","source":"simplywall.st","summary":"A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA - simplywall.st","headline":"A Look At Cogent Biosciences (COGT) Valuation After FDA Acceptance Of Bezuclastinib NDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQNUZoX0ljWVc2eERmUHc4T2dCNUxaSlBObE9mTU1ZVnNhWUhZWXc1Y0hXYUdQRWJ6Z2dyZi1xbGFzdmk5dHdDdVBKSDh0dWM2Q2FnNk5nQkd4RlpKU3BLamZKQVoyVFp2d09LVW54aGF5blpyamRwY3FmSWlMNjBOV0tmRlJPc1lfbnpBQmhLVWNSQWZjQWNzUzFiN1d6SGNPNGlhcE5PdFJTOUN4NjhIOHR0cGwwYkY1ZkdRN2lQLUNpa3lpdU13WEpuVjhxSGNaazFiNkFXLVhHaFlVSEE?oc=5","date":"2026-03-17","type":"regulatory","source":"The Globe and Mail","summary":"COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - The Globe and Mail","headline":"COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPT0dYRzJzX0tnWUQ4U3F3TjR6UHFaVFBTVTZqUlFiMkZ2UjliLTh3WnJjX2IyZ3V2YjlWYld6RjRTUWZoZS1UbDlhRHlPS2lHMlREZXg0LTBuVlBIQ2QtUDREb0J0ZjZYdHpyWEk3LW1oUGFFTGZJVXhYN1RRbDJVWldScWM5ZGZjdmZseVoyOWFEU0RYWjhuQ1FxOVRPSmtjNGwtYm0tYTRmSTRpQ3hELU9R?oc=5","date":"2026-03-04","type":"regulatory","source":"Seeking Alpha","summary":"Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish (NASDAQ:COGT) - Seeking Alpha","headline":"Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish (NASDAQ:COGT)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQeDRYS2hwenFmcjJDRzZ4VGxYSFdsdTZGWlQ1cXJmOWdTcnBNa2EyNndadWZhLVhqMFBYdS1IYkNrckMyVnZIazlkLVlIRGdOSmJDNVV3Y1hMNjhIVzE5SENBSW1XMVl4U2tmVFlScHN0UHpCekNKc0xkV0ZPQzZLbkFhS3MzbWQ1anlFSG5idE5yRW5oS2h4SFhieW92Y2hsLXd2aFZJVTBqSm1qNXZOTWFWamRZWGwtNjRwVHd6eWM5N2lsQ2lEN1JXMUo5cGE0MEpRU1pmbGVtWWs0N1dnbWNjcU9TNUE?oc=5","date":"2026-02-17","type":"trial","source":"The Motley Fool","summary":"Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - The Motley Fool","headline":"Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough","sentiment":"positive"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOcUVHRS1WSWRWYmdsaVozcGdiWHcwOXJZa01yX1BqTTFUZjdzWlIyNGZWMkhSQWtSaFZHYUJYSmNZenNZNWxfN2ctS1M1U1FlQ1FtODVsMUZISVIzc1h1RmVuUG9HZFRwbHZIYnJxN0ZuRXJFZ3pyT1lfMmdDU0lnM0tsU0tLZlloRS1kVzVweEk3VllVamJLMGl5Q3A0Y0NNMVFraA?oc=5","date":"2025-12-30","type":"regulatory","source":"TechStock²","summary":"Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - TechStock²","headline":"Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPcXlRcDlnMHJoM2N2NUNORWRRMXFYVEZYZzYtQWRQdEROVzJyTEFPWDlNSmJoNjFmYVhRNFF4emFDdzdIOS04QU5qWjB2MTJ6TExMaFZTUmJ2TjZoTUNaaHZFcVJfQ1hwYVViX0lnT1IwYktSS2Jjb3ZsTE1Sd1R2TmFLMklsb3p6?oc=5","date":"2025-11-10","type":"pipeline","source":"Barron's","summary":"Cogent Biosciences Stock Surges 136%. Why Investors See Promise in Its Cancer Drug. - Barron's","headline":"Cogent Biosciences Stock Surges 136%. Why Investors See Promise in Its Cancer Drug. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNS0x3VjBYMFRaNjNIYWFZSXJvQnh0WXhENTlhNnkwVDJZX21qOFR4WDg3TFFSbG1rWjF3XzBFTjJQcS03eVF3UTJMQnVHNFdXeUVXTlEwZ0oxNTRMUXk3T2VROXJrSWxYOFZ0czRwN2VDOHV6akU4Q1BDU2pJVVBUXzBhLXZmZlB0Ym9CelI0WnctWkQtWUdjc3NCbTJKa1AyYmlsQ1c3b1F0RGZxY09yaGhzT2FSTDI5VFl0dkFmQ0MzS3hRaHJYdjdPLTE3RjFjdVFyVEdGNTF5YnBaSWk3M0JjVEJobzJKUHN0WDVTZ0l1bFZjTHAtLVhUd3JNUnAtMVgzWjdEdUwydzFjZjdpVkZZZjNIVVZUVmx1WTIxR0hpZw?oc=5","date":"2025-11-10","type":"earnings","source":"Benzinga","summary":"Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Bi - Benzinga","headline":"Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Bi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE8tNHdVUkQzbGJKdENXRHpmQ2RNd01TaDhyMWFMMjRuYmVaemN6d0NacDNfYUJSSU50a1l0NWIwZmZTdElGUlBqRWRMcHlmX0hzX1FrOFhiX3laaVVpdDZ6SXAwMnBneEFNYXdkVU9ZeWVrMGRJZU1RTjAyR1hvRjQ?oc=5","date":"2025-08-26","type":"pipeline","source":"Seeking Alpha","summary":"Cogent Biosciences: Moving Forward (NASDAQ:COGT) - Seeking Alpha","headline":"Cogent Biosciences: Moving Forward (NASDAQ:COGT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9mdlBUNDVhWTBhVXAybUlqNW9xQ0VFYVdjdDJwdjluX2FsS25wWHUxWHhSZGhkSTlTMlRoVFFFNHFfYm93V1E4R09GTFJwa2pjbGRTb0hWOFBBcFdIMHdZRDdER3hnMU1pTi1saHZlVm1iM0habVkyVU9Jd1c?oc=5","date":"2025-07-08","type":"trial","source":"Yahoo Finance","summary":"COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Yahoo Finance","headline":"COGT Stock Soars on Phase III Systemic Mastocytosis Study Success","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE0wVmVhRzczcGtuSjNZdWpITTJ3NlljR2RBQnd2VkRlWlJKX1NadW9pOThWdlFnd1RtUFhqVDZDUGZ4ZnFkZEp3dXBsaXJ3ck9PbFk0?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"COGT Stock Price, News & Analysis | Cogent Biosciences - Stock Titan","headline":"COGT Stock Price, News & Analysis | Cogent Biosciences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxQM1ZzUmtsNTV5T2hpNmVYck5zQUpBcmF0MlJQOEFPQ2lQeHVRRmxNSzFkcGgwb3R1WjJKd1FzSzNtc1lCZFhmcFFjU0RPZ1NMUHlheXJKQ3dMSGw3UjFkRzF3TEwtaHJhaFhRdDg2ZkR0SFlXR1VlTDBBeWZPTUZGcnRlRHNyTEJpWE9OckoxTkJKSS1SeUQycmM0bmJHbGwxaEJic1YzcnFKclFQOHpUMkJXNl9zUXR2V21FZGIxWjRnR3V1THd3cVVZYkRjQ3JYOHhtZHEwNHI2amktcHZhbTZEV25oY0tFZ3QydVV4QmRNTzFYU3dZZHlyWlU1WXVHa18yWGI1Zk9IUDlkREdBSk9DOURGNW9KUWpqbXkwblV0MVhxX0I5OXFUQTVHVnVfOVBmLXJB?oc=5","date":"2025-01-13","type":"pipeline","source":"globenewswire.com","summary":"Cogent Biosciences Announces Planned 2025 Milestones for - globenewswire.com","headline":"Cogent Biosciences Announces Planned 2025 Milestones for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5MUV83NDU3NUdBYUh3V1RQR3ljRXB4ZTI0YVdCZzU0WlAyRzI2al83T0NKZW1oc0Y2TExhN08zdUt2MUFfcXduc1JUSmlOMDFZ?oc=5","date":"2023-12-12","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"ezurastat","drugSlug":"ezurastat","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Amgen","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":269780000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-328937000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":937607000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}